Next-Generation Antibody Therapeutics Market
The increasing number of technological developments in the healthcare industry,
is one of the major factors fuelling the surge in the demand for next-generation antibody therapeutics solutions throughout the globe.
For instance,
there have been major developments in the healthcare technologies over the last few years,
such as the development of bispecific antibodies (BsAbs), ADC technologies, and glycoengineered antibody.
These advancements have significantly increased the application area of the antibody therapeutics.
The other major factor propelling the demand for next-generation antibody therapeutics solutions,
is the increasing prevalence of chronic diseases across the world.
ADCs are widely considered to be much safer and effective than the conventionally used antibodies for cancer treatment,
as these are made by combining a biologically active cytotoxic drug and a monoclonal antibody for targeting the tumor cells.
This also plays a major role in overcoming the challenges occurring because of the limited utilization of the monoclonal antibody therapeutics.
Due to these factors, the global next-generation antibody therapeutics market is expected to exhibit huge growth in the coming years.
The global next-generation antibody therapeutics market is set to exhibit substantial growth in the coming years.
The prominent factors driving the expansion of the market are the rapid technological advancements,
the rising incidence of cancer,
and the surging number of collaborations among various market players in order to develop next-generation antibody therapeutics.
In addition to this,
the rapidly improving infrastructure for life sciences research is massively boosting the advancement of the market across the globe.
The development of antibody drug conjugates (ADCs),
bispecific antibodies (BsAbs), and glycoengineered antibodies has augmented the application areas of antibody therapeutics.
ADCs are more effective and safer than the conventionally used antibodies in cancer treatment,
as they are made by combining a biologically active cytotoxic drug and a monoclonal antibody for targeting tumor cells.
This helps overcome the existing challenges of limited applications of monoclonal antibody therapeutics.
Therefore, it can be said that rapid technological advancements are fueling product innovations.
This is, in turn, propelling the growth of the next-generation antibody therapeutics market. Based on technology, the market is classified into ADCs, BsAbs, biosimilar antibody (Ab) products, Fc engineered antibodies, and antibody fragments and antibody-like proteins (AF & ALPs). Out of these, the ADCs category is predicted to record the highest growth in the market in the future years. The Fc engineered antibodies category is predicted to exhibit the fastest growth in the market in the forthcoming years.
When therapeutic area is taken into consideration, the market is divided into oncology and autoimmune/inflammatory categories. Between these, the oncology category is predicted to hold huge revenue share in the market during the next few years. On the other hand, the autoimmune/inflammatory category will exhibit rapid expansion in the global market in the years to come, as per the estimates of P&S Intelligence, a market research company based in India.
One of the major trends witnessed in the next-generation antibody therapeutics market is the rising popularity of the ADC technology. The cytotoxic characteristic nature of antibodies is predicted to be very beneficia in chemotherapy. This characteristic is regulated and expressed by the ADC technology for increased specificity and efficacy.
Due to the high efficiency of ADCs,
biotechnology and pharmaceutical firms all over the world are heavily focusing on developing ADCs.
There are different types of technologies adopted for the development of next-generation antibody therapeutics solutions such as antibody drug conjugates (ADCs), Fc engineered antibodies, biospecific antibodies (BsAbs), antibody fragments and antibody-like proteins (ALPs & AF), and biosimilar antibody (Ab) products. Out of these, the ADCs recorded the highest usage in the last few years. The Fc engineered antibodies are expected to register rapid growth in demand in the coming years.
The biggest trend currently being witnessed in the next-generation antibody therapeutics market is,
the rising adoption of ADC technology in various applications.
It has been found that the cytotoxic nature of antibodies have potentially huge benefits in chemotherapy,
which are regulated and expressed by the ADC technology in order to achieve higher specificity and enhanced efficacy.
Due to the high efficiency provided by the ADCs,
many biotechnology and pharmaceutical companies across the world are rapidly shifting their focus toward the development of ADCs.
Thus, the surging cases of cancer will accelerate the next-generation antibody therapeutics market at a healthy CAGR in the coming years. In contemporary times, antibody drug conjugates (ADCs), the next-generation antibodies, are being considered as a safer and effective option for treating cancer, as these antibodies are prepared by combining a biologically active cytotoxic drug and monoclonal antibody to target tumor cells. These antibodies help in overcoming the challenge of the limited application of monoclonal antibody therapeutics.
Nowadays, the ADC technology is gaining traction due to the cytotoxic nature of such antibodies,
as they offer a high potential benefit in chemotherapy.
This property of ADCs delivers improved efficacy and enhanced specificity.
Owing to the high efficiency offered by this technology,
biotechnology and pharmaceutical companies across the globe are increasingly focusing on the development of ADCs.
For instance, Seattle Genetics Inc., F. Hoffmann-La Roche AG, and Bristol-Myers Squibb Company are involved in the development of ADC technology-enabled next-generation antibody therapeutics solutions.
Apart from ADCs, Bayer AG, Xencor Inc., Dyax Corp., Takeda Pharmaceuticals Company Ltd., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., ImmunoGen Inc., Amgen Inc., and AstraZeneca PLC are also engaged in the production of Fc engineered antibodies, biosimilar antibody (Ab) products, bispecific antibodies (BsAbs), and antibody fragments and antibody-like proteins (AF & ALPs). In the coming years, Fc engineered antibodies will be consumed at the highest rate. These next-generation antibodies are being used in oncology and autoimmune/inflammatory therapeutic areas.
The surging use of next-generation antibody therapeutics can also be attributed to the numerous initiatives being taken by several government organizations for improving healthcare infrastructure and encouraging research in this field. The soaring government support toward this field is because of their higher effectiveness than conventional therapeutics for treating cancer, autoimmune disorders, and inflammatory diseases. Extensive government support in research is encouraging pharmaceutical and biotechnology firms to heavily invest in the development of new antibodies.
According to P&S Intelligence, North America led the next-generation antibody therapeutics market in the past, and it is also expected to retain its market dominance in the coming years as well.
This can be credited to the strong presence of prominent players, presence of well-developed life sciences research infrastructure.
and increased anti-body research activities, in the region. Additionally, the growing prevalence of chronic health disorders such as cancer and surging government support for R&D in antibody therapeutics will encourage the adoption of next-generation antibody therapeutics in North America.
Globally,
North America is predicted to observe rapid growth in the utilization of next-generation antibody therapeutics solutions in the coming years. This is mainly attributed to the presence of major antibody therapeutics solutions developing and providing companies, rising incidence of chronic diseases, existence of well-developed life sciences research facilities and infrastructure, and the increasing implementation of government measures and policies in several countries for promoting research and development (R&D) activities in antibody therapeutics solutions, in the region.
The worldwide next-generation antibody therapeutics market is predicted to grow significantly in the coming years.
The rising cancer prevalence, technical breakthroughs, and growing number of partnerships among market participants for the development of next-generation antibody therapies are all driving the market expansion. Furthermore, the industry advance is aided by the development of biosciences research infrastructure, widening of the applications of such medicines, and government support for associated research.
Many government organizations in various nations have launched measures to promote research and improve healthcare infrastructure. Such endeavors are assisting in the development of next-generation antibody therapies that have proven more successful than traditional medicines in the treatment of inflammatory illnesses, cancer, as well as autoimmune disorders. This encourages biotech and pharmaceutical businesses to invest in the next-generation antibody therapeutics market, considering the continuously rising prevalence of chronic autoimmune and inflammatory diseases, as well as cancer.
Antibody drug conjugates (ADCs), Fc engineered antibodies, antibody fragments and antibody-like proteins (AF & ALPs), biosimilar antibody (Ab) products, as well as bispecific antibodies are the categories under the next-generation antibody therapeutics market technology segment. ADCs accounted for the highest market revenue in the past, while Fc engineered antibody usage is expected to increase at the quickest rate over the forecast period. Antibodies’ cytotoxic (cell-killing) properties are thought to offer strong benefits in chemotherapy.
The ADC technology expresses and regulates this feature for greater efficacy and specificity. Pharmaceutical and biotechnology companies throughout the world are progressively promoting the development of ADCs due to their great efficiency. Although the creation of an ADC may appear to be simple, various factors must be considered in order to fully realize an ADC’s potential as a cancer treatment agent. The immunogenicity of an antibody is used in the ADC technology to house a chemically supertoxic substance into tumor cells, whereas the delivery of an unconjugated drug by itself is not viable due to its high toxicity.
another among the key driving factors for the next-generation antibody therapeutics market is technological advances.
The advancement of glycoengineered antibodies, BsAbs, and ADCs has broadened the scope of antibody treatments.
Because ADCs are made by merging a monoclonal antibody as well as a bioactive cytotoxic chemical to target tumor cells,
they are regarded safer and more effective than standard antibodies for cancer treatment.
This also aids in overcoming the issue of mAb therapies’ limited use.
the market will continue to grow with the advancing field of cancer treatment and research, aided by government funding, with the aim to reduce treatment costs and mortality.
Therefore, it can be concluded that owing to the rising technological advancements in antibody therapeutics solutions and healthcare industry, increasing incidence of chronic diseases, surging geriatric population, and the numerous benefits provided by the next-generation antibody therapeutics solutions in various healthcare applications, their demand is expected to skyrocket throughout the world in the coming years.
